CN112076204A - Application of nicotinamide mononucleotide in motor neuron repair - Google Patents
Application of nicotinamide mononucleotide in motor neuron repair Download PDFInfo
- Publication number
- CN112076204A CN112076204A CN202011052049.3A CN202011052049A CN112076204A CN 112076204 A CN112076204 A CN 112076204A CN 202011052049 A CN202011052049 A CN 202011052049A CN 112076204 A CN112076204 A CN 112076204A
- Authority
- CN
- China
- Prior art keywords
- nicotinamide mononucleotide
- application
- motor neuron
- motor neurons
- repair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of nicotinamide mononucleotide in repairing motor neurons, which comprises the step of applying nicotinamide mononucleotide in repairing motor neurons, wherein the nicotinamide mononucleotide is wrapped by a lipid carrier to form a treatment unit, and the lipid carrier is a cell membrane-like extract. The invention applies the nicotinamide mononucleotide to repair motor neurons of human or animals, and particularly adopts a drug administration mode of affinity to human or animal cells, so that the curative effect of the nicotinamide mononucleotide can be further improved.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of nicotinamide mononucleotide in motor neuron repair.
Background
Since motor neuron diseases are common and frequent and occur in all ages, men, women, old and young people have symptoms, and in the current market, many medicines for treating the motor neuron diseases exist, and the curative effect of most medicines is not good along with the improvement of the drug resistance of patients. Often, patients are not able to confirm that current drugs cause certain side effects and how to maintain a long-lasting efficacy, and for this reason, it is of great importance to find a long-lasting and side-effect-free drug therapy.
Correspondingly, as a substance endogenous to the human body, the nicotinamide mononucleotide is one of important parts of the coenzyme synthesized in the human body, the increase of the content of the nicotinamide mononucleotide is beneficial to the improvement of various functions of the human body, and the nicotinamide mononucleotide is a therapeutic drug without a plurality of side effects and has an outstanding therapeutic effect on the restoration of the intrinsic loss of the human body. For diseases such as motor neurons, the main treatment of the diseases is the repair and treatment of the motor neurons, and the damaged parts of the motor neurons are constructed again fundamentally. Therefore, the research on the application of the nicotinamide mononucleotide in the motor neuron repair is of great significance, and the nicotinamide mononucleotide is helpful for providing revelation for the treatment of related diseases.
Disclosure of Invention
The invention aims to provide application of nicotinamide mononucleotide in repairing motor neurons, and aims to solve the problems in the background technology. In order to realize the purpose, the invention adopts the technical scheme that:
the application of nicotinamide mononucleotide in repairing motor neuron is to apply nicotinamide mononucleotide in repairing motor neuron.
Further, the nicotinamide mononucleotide is encapsulated by a lipid carrier to form a therapeutic unit.
Further, the lipid carrier is a cell membrane-like extract.
In the application process of the nicotinamide mononucleotide of the invention, for the administration, a large number of comparative experiments can be carried out, and the nicotinamide mononucleotide has corresponding effect on repairing motor neurons, and the further optimization of the administration form enables the effect of the nicotinamide mononucleotide to be further optimized.
The invention has the beneficial effects that: through combining nicotinamide mononucleotide (nicotinamide mononucleotide) with different cell affinity carriers, the continuous treatment of the nicotinamide mononucleotide on the motor neurons is completed, the motor neurons can be well repaired, and the motor capacity is recovered and improved.
Detailed Description
In order that the invention may be more fully understood, reference will now be made to the following description. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
It will be understood that when an element is referred to as being "secured to" another element, it can be directly on the other element or intervening elements may also be present. When an element is referred to as being "connected" to another element, it can be directly connected to the other element or intervening elements may also be present. In contrast, when an element is referred to as being "directly on" another element, there are no intervening elements present. The terms "vertical," "horizontal," "left," "right," and the like as used herein are for illustrative purposes only and do not represent the only embodiments, and the terms "upper," "lower," "left," "right," "front," "rear," and the like as used herein are used in a positional relationship.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
The technical solution of the present patent will be described in further detail with reference to the following embodiments.
The embodiment of the invention provides an application of nicotinamide mononucleotide in repairing motor neurons, and the nicotinamide mononucleotide is applied to repairing the motor neurons.
In this embodiment, nicotinamide mononucleotide is encapsulated by a lipid carrier to form a therapeutic unit.
In this embodiment, the lipid carrier is a cell membrane-like extract, and in this embodiment, the lipid carrier specifically carrying nicotinamide mononucleotide is extracted from the lipid structure of animal cell membrane according to the actual administration object, and the lipid is wrapped around the nicotinamide mononucleotide to form a therapeutic unit.
In the embodiment, a weight-bearing swimming experiment of a mouse is taken as a verification scheme, the experiment is a conventional experiment which is often used for evaluating the sports fatigue of the mouse, and the experiment is mainly applied to the process of developing new medicaments and verifying the effect of the experiment so far. In contrast, in the scheme adopted by the invention, the step verification of the application comprises the following steps:
s1: taking SPF-level mice, wherein the male mice and the female mice are 30 respectively, and the body weight difference value is maintained within the range of 20 +/-2 g;
s2: after the mice are distinguished according to the sex, the mice are correspondingly and randomly divided into 3 pairs of experimental groups, and corresponding model establishment is carried out by combining different applications of nicotinamide mononucleotide products, wherein a model group (injected with normal saline), a control group A (conventional nicotinamide mononucleotide reagent) and a control group B (injected with the reagent of the invention) are respectively arranged;
s3: tying 5g of lead blocks at the tail end of a mouse, simultaneously putting the mouse into a beaker with the water temperature of 25 ℃, and detecting the swimming endurance of the mouse until the limit value of the swimming endurance of the mouse is that the mouse does not float upwards for 10s when sinking into the bottom of the cup;
s4: the experiment uses SPSS 18.0 statistical software to carry out one-factor variance analysis and time t test, data of a rat tested in the experimental process are expressed by mean number plus or minus standard deviation (x plus or minus s), the difference with P less than 0.05 is taken as statistical significance, and the average endurance value of each group of mice is respectively calculated to obtain the following table.
In the endurance test of mice, the damage degree caused by the strenuous exercise of mouse motor neurons in a certain time is reflected, and the main means for relieving the neuron damage lies in the neutralization reaction of in-vivo biological enzymes to related substances of organisms in the exercise process. Compared with the experimental data of the control group and the administration group, the effect brought by the administration group is obviously incomparable with the control group, and besides, the mode of using the lipid to complete the package administration of the nicotinamide mononucleotide, which is defined by the invention, further improves the reach rate and the use effect of the nicotinamide mononucleotide.
The above embodiments are only for illustrating the invention and are not to be construed as limiting the invention, and those skilled in the art can make various changes and modifications without departing from the spirit and scope of the invention, therefore, all equivalent technical solutions also belong to the scope of the invention, and the scope of the invention is defined by the claims.
Claims (3)
1. The application of nicotinamide mononucleotide on motor neuron repair is characterized in that: nicotinamide mononucleotide is applied to the repair of motor neurons.
2. The use of nicotinamide mononucleotide for motor neuron repair according to claim 1, wherein: the nicotinamide mononucleotide is encapsulated by a lipid carrier to form a therapeutic unit.
3. The use of nicotinamide mononucleotide for motor neuron repair according to claim 2, wherein: the lipid carrier is cell membrane-like extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011052049.3A CN112076204A (en) | 2020-09-29 | 2020-09-29 | Application of nicotinamide mononucleotide in motor neuron repair |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011052049.3A CN112076204A (en) | 2020-09-29 | 2020-09-29 | Application of nicotinamide mononucleotide in motor neuron repair |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112076204A true CN112076204A (en) | 2020-12-15 |
Family
ID=73729799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011052049.3A Pending CN112076204A (en) | 2020-09-29 | 2020-09-29 | Application of nicotinamide mononucleotide in motor neuron repair |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112076204A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108025187A (en) * | 2015-04-28 | 2018-05-11 | 新南创新私人有限公司 | Targeting NAD+ is to treat cognitive impairment, neuropathy that chemotherapy and radiotherapy trigger and inactive |
| CN108697722A (en) * | 2015-10-02 | 2018-10-23 | 麦德龙国际生物科技有限责任公司 | The crystal form of β-nicotinamide mononucleotide |
| CN112203650A (en) * | 2018-06-21 | 2021-01-08 | 雀巢产品有限公司 | Nicotinamide Adenine Dinucleotide (NAD) is used+) Compositions and methods of precursors and at least one ketone or ketone precursor |
-
2020
- 2020-09-29 CN CN202011052049.3A patent/CN112076204A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108025187A (en) * | 2015-04-28 | 2018-05-11 | 新南创新私人有限公司 | Targeting NAD+ is to treat cognitive impairment, neuropathy that chemotherapy and radiotherapy trigger and inactive |
| CN108697722A (en) * | 2015-10-02 | 2018-10-23 | 麦德龙国际生物科技有限责任公司 | The crystal form of β-nicotinamide mononucleotide |
| CN112203650A (en) * | 2018-06-21 | 2021-01-08 | 雀巢产品有限公司 | Nicotinamide Adenine Dinucleotide (NAD) is used+) Compositions and methods of precursors and at least one ketone or ketone precursor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772407B (en) | Pharmaceutical composition for promoting nerve damage restoration and application thereof | |
| WO2006123248A3 (en) | Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject | |
| CN101649311B (en) | Preparation method of human lysozyme-antibacterial peptide Catesbeianin-1 fusion protein and application of same on preventing and curing cow mastitis | |
| Tabor et al. | Corneal damage due to eye contact with chlorhexidine gluconate | |
| CN101779609A (en) | Method for establishing male rhesus macaque chronic Parkinson disease model by using low-dose MPTP | |
| CN103005466A (en) | Application for drone pupae polypeptide extract | |
| CN114259507B (en) | Application of klebsiella minutissima in preparing medicine for treating and/or preventing hyperuricemia related diseases | |
| CN1238033C (en) | Medicine composition for treating neurasthenia | |
| CN112076204A (en) | Application of nicotinamide mononucleotide in motor neuron repair | |
| CN102085371B (en) | Medical gargle product for Xerostomia and preparation method thereof | |
| CN102150860B (en) | Composition for easing visual fatigue and assisting in improving memory | |
| CN101269156A (en) | Chinese medicinal composition for treating eye disease | |
| Contributors | Human physiology | |
| WO2015070386A1 (en) | Dietary nutritional supplement for preventing elderly osteoarticular diseases | |
| CN109276688B (en) | Traditional Chinese medicine composition for senile dementia | |
| CN104399060A (en) | Application of metallothionein composite preparation in preparation of drugs for acupoint intervened treatment of cerebral apoplexy sequelae | |
| Javadi et al. | Effect of nutrition training and exercise training alone and together on body weight of overweight women referred to health centers in Qazvin | |
| CN104839689A (en) | Health product for invigorating spleen, nourishing stomach, resisting fatigue and enhancing immunity | |
| CN105343132A (en) | Composition for treating colitis, medicine and preparing method thereof | |
| JP2006342153A (en) | Locust hydrolysate, its production method and locust hydrolysate compounding agent | |
| CN102784172A (en) | Compound probiotics for treating irritable bowel syndrome and preparation method thereof | |
| Belenichev et al. | Reduction of apoptotic death of neurons СА-1 zone of hippocampus of rats in the condition of prenatal chronic alcoholisation by cerebrocurin and tiocetam | |
| CN103356700A (en) | Joint maintaining ointment | |
| CN106509761A (en) | Health-care product having cell repair factors and effects of building body, beautifying features and prolonging life | |
| CN1159025C (en) | Chinese medicine for optimally taking care of brain health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201215 |
|
| RJ01 | Rejection of invention patent application after publication |